This Hospital Stock Rises 276% in 5 Years: From Post-Covid Recovery to a UK Bet

This hospital stock has turned Rs 1 lakh into roughly Rs 3.76 lakh over five years. One multi-speciality healthcare operator delivered a 5-year return of 275.94% as of 10 September 2026, ranking 28th in a screen of 101 large-cap and mid-cap NSE shares.

The company is Narayana Hrudayalaya Ltd (NSE: NH), the Bengaluru-based chain founded by cardiac surgeon Dr Devi Prasad Shetty and better known as Narayana Health. The Narayana Hrudayalaya share price closed at approximately Rs 1,909.70 on 10 September 2026, up about 1% on the day, giving the company a market value of around Rs 38,600 crore. The rally was built in two phases: a sharp post-Covid profit recovery in India and the Cayman Islands, followed by a bold overseas expansion into the UK.

Click Here – Get Free Investment Predictions

How Much Has This Hospital Stock Returned Across Periods?

The long-term numbers for this hospital stock are strong, but the recent ones are more modest. This hospital stock is a clear five-year winner, while its one-year and six-month returns sit in the middle of the pack.

Period	Return	Rank (out of 101)
1 Month	3.30%	56
6 Months	15.84%	70
1 Year	10.39%	71
3 Years	75.06%	57
5 Years	275.94%	28

The gap between the 5-year and 1-year figures tells the story. Most of the hospital stock gains came between FY22 and early FY26, when earnings more than doubled. Over the last twelve months, the hospital stock has gained only about 10%, as investors weighed a large acquisition against thinner margins.

The Narayana Hrudayalaya share price now trades between a 52-week low of Rs 1,589 and a 52-week high of Rs 2,093.30. At around Rs 1,910, the hospital stock sits roughly 9% below that peak and about 20% above the low. There has been no stock split or bonus issue in the period, so the 275.94% figure reflects genuine price appreciation.

Why Did This Hospital Stock Rise 276% in 5 Years?

The short answer is earnings growth at this hospital stock. Net profit rose from approximately Rs 342 crore in FY22 to Rs 810 crore in FY26, while revenue more than doubled from Rs 3,736 crore to Rs 7,996 crore. A hospital stock that grows profit this fast usually gets re-rated, and that is what happened here.

Post-Covid Recovery Lifted Hospital Stock Earnings

Five years ago, this hospital stock was still recovering from the pandemic, when elective surgeries and international patient flows had dried up. As occupancy returned, operating margins expanded from 18.62% in FY22 to 23.11% in FY23 and 25.37% in FY24.

Net profit nearly doubled in FY23 to approximately Rs 607 crore and climbed to around Rs 786 crore in FY24. That phase, where each extra patient added more to profit than to cost, drove the first big leg of the rally.

Cayman Islands Became a High-Margin Engine

The Health City Cayman Islands business turned into a key profit driver for the hospital stock. During Q2 FY26, the Cayman unit contributed over 25% of revenue with an EBITDA margin of about 44%, far above the roughly 24% margin of the Indian operations.

Cayman revenue grew approximately 38.9% year on year to Rs 551 crore in Q1 FY27, supported by the group's One Health insurance platform. For a hospital stock, a dollar-earning overseas unit with such margins is a rare advantage.

India Business Shifted Toward Complex Care

In India, the company focused on high-end procedures such as cardiac surgery, robotic surgery and advanced ablation. India revenue rose about 17% year on year to Rs 1,325 crore in Q1 FY27, with 2,137 cardiac surgeries performed at the Bengaluru hub alone.

The group now runs 55 healthcare facilities across three countries, with over 5,900 operational beds. New greenfield hospitals in Kolkata and Bengaluru are planned to add capacity through FY29.

UK Acquisition Added a New Growth Leg

In late 2025, the hospital stock made its biggest move yet and agreed to buy Practice Plus Group Hospitals, the fifth-largest private hospital chain in the UK, for approximately Rs 2,200 crore in an all-cash deal. The network of 12 hospitals and surgical centres performs around 80,000 surgeries a year, mainly in orthopaedics, ophthalmology and general surgery.

The deal closed on 6 November 2025 at around 12 times EV/EBITDA. Paired with strong Q2 FY26 results, the news helped the hospital stock jump about 14% in three sessions, taking its 2025 gain to roughly 57% at that point.

Hospital Stock Sector Tailwinds

The broader Indian hospital sector is expected to grow at around 10% to 11% a year over the next three to five years. Rising lifestyle diseases, wider health insurance coverage and medical tourism all support demand for every listed hospital stock, and this hospital stock has benefited from these trends more than most.

Put simply, this hospital stock combined steady domestic growth, a profitable overseas franchise and a willingness to pursue acquisitions. Few listed peers offer that mix of geographies, which is one reason the hospital stock has attracted long-term institutional money.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Narayana Hrudayalaya Share Price and Financial Performance

Revenue at this hospital stock has jumped since the UK deal, but profit has not kept pace. The table below shows the last five quarters on a consolidated basis.

Quarter	Revenue (Rs Cr)	EBITDA (Rs Cr)	Net Profit (Rs Cr)	Net Margin
Jun 2025 (Q1 FY26)	1,531	361	197	13.0%
Sep 2025 (Q2 FY26)	1,668	427	259	15.7%
Dec 2025 (Q3 FY26)	2,174	390	127	7.8%
Mar 2026 (Q4 FY26)	2,623	539	224	8.8%
Jun 2026 (Q1 FY27)	2,719	505	207	7.7%

In Q1 FY27, reported on 1 August 2026, operating revenue rose about 78% year on year to approximately Rs 2,684 crore. The UK business contributed around Rs 826 crore. EBITDA grew roughly 40% to Rs 505 crore, but the margin fell to 18.8% from 23.9% because UK hospitals run at thinner margins.

Net profit rose only about 5% to Rs 207 crore. Employee costs more than doubled, interest expense nearly doubled and depreciation rose by about 85%, all linked to the acquisition. This explains why the Narayana Hrudayalaya share price has cooled despite the revenue surge.

For FY26 as a whole, revenue grew about 43% to Rs 7,996 crore, while net profit rose only 2.6% to Rs 810 crore. Operating cash flow was strong at approximately Rs 1,621 crore, which helps fund ongoing capex.

Who Owns This Hospital Stock?

Promoters hold a steady majority in this hospital stock, while foreign investors have trimmed their stake. The shareholding trend over five quarters is below.

Quarter	Promoters	FIIs	DIIs	Public
Jun 2025	63.85%	10.46%	8.09%	17.60%
Sep 2025	63.85%	10.49%	7.76%	17.90%
Dec 2025	63.27%	11.10%	7.91%	17.71%
Mar 2026	63.27%	9.98%	9.15%	17.59%
Jun 2026	63.27%	9.40%	9.06%	18.27%

The Shetty family holds about 63.27%, with Shakuntala Shetty owning roughly 34.8% and Dr Devi Prasad Shetty around 11.66%. The small dip in late 2025 was a minor stake sale by one promoter.

FII holding has slipped from a peak of 11.10% in December 2025 to 9.40% in June 2026. Domestic institutions moved the other way, rising to about 9.06%, led by mid-cap and flexi-cap mutual funds. Biocon founder Kiran Mazumdar-Shaw also holds approximately 2.3% as a public shareholder.

Valuation: Is This Hospital Stock Expensive?

On trailing earnings, the hospital stock valuation is not stretched compared with peers. The stock trades at a PE of approximately 47 against an industry PE of around 68, a discount that reflects its lower recent profit growth.

The price-to-book ratio is about 8.5 and return on equity is around 17.8%. However, debt-to-equity has risen to approximately 1.29 on gross borrowings, up from 0.62 in FY25, because the UK deal was funded mainly with debt. Management reports net debt-to-equity of about 0.42 after adjusting for cash.

Compared with the five-year average, the hospital stock now trades at a lower multiple of earnings, because profit growth slowed while the share price paused. If margins recover, that gap could narrow. If they do not, the shares may stay range-bound for longer.

Key Risks for This Hospital Stock

UK integration risk: The Practice Plus Group business earns thinner margins and depends partly on NHS referrals. Any policy change or slower integration could keep consolidated margins under pressure.

Higher debt: For this hospital stock, long-term debt has more than doubled to around Rs 4,667 crore, including dollar and sterling loans. Interest coverage has dropped to about 5.4 times, the lowest in recent quarters, and currency moves can swing reported numbers.

Margin dilution: Net margin has fallen from about 15.7% in Q2 FY26 to 7.7% in Q1 FY27. If the UK unit does not improve, profit growth may lag revenue for several quarters.

Cayman concentration: A large share of profit comes from one island market. A slowdown in US medical tourism or local insurance changes would hit this hospital stock hard.

Capex execution and regulation: New hospitals in Kolkata and Bengaluru take time to break even. In India, price caps on procedures or government scheme rates can also limit pricing.

Download the Univest iOS App or Univest Android App to track the Narayana Hrudayalaya share price live

Narayana Hrudayalaya Share: Analyst View

Most analysts remain positive on the long-term hospital stock story but want proof that UK margins will improve. The Narayana Hrudayalaya share has held up better than many peers in 2026, though it still trades below its 52-week high.

Narayana Hrudayalaya Share Price Target

The highest recent Narayana Hrudayalaya share price target is Rs 2,310, set by a domestic brokerage in June 2026 with a Buy rating. Another domestic brokerage set a Narayana Hrudayalaya share price target of Rs 2,250 in May 2026, while the consensus of tracking analysts stood at approximately Rs 2,152 in July 2026.

From around Rs 1,910, these imply upside of roughly 13% to 21%. Not every view is bullish: one domestic brokerage had a Hold rating with a Narayana Hrudayalaya share price target of Rs 1,817 in March 2026. Key levels to watch are the 52-week high of Rs 2,093.30 on the upside and the Rs 1,589 low on the downside.

What Should Investors Track Next in This Hospital Stock?

Three things matter most over the next few quarters. First, UK EBITDA margins, which need to improve as integration progresses. Second, the pace at which new Indian beds fill up. Third, the trend in debt and interest costs, which now eat into profit.

A hospital stock with rising occupancy, stable Cayman margins and falling debt would likely regain momentum. Quarterly results in November 2026 will be the next key checkpoint.

Conclusion

This hospital stock earned its 276% five-year gain the old-fashioned way, by more than doubling profit through a post-Covid recovery, a high-margin Cayman business and a push into complex care. The Narayana Hrudayalaya share price rewarded that growth until 2025, then paused as the UK acquisition diluted margins and raised debt.

The next leg depends on whether the UK business can lift profitability and whether new Indian capacity ramps up on time. Investors tracking this hospital stock should watch quarterly margins, debt levels and UK performance before adding to positions, and should consult a SEBI-registered advisor.

Frequently Asked Questions

Which hospital stock rose 276% in 5 years?

Ans. Narayana Hrudayalaya Ltd (NSE: NH), which runs Narayana Health hospitals, is the hospital stock that returned approximately 275.94% over five years as of 10 September 2026. It ranked 28th among 101 large-cap and mid-cap NSE stocks screened.

Why did the Narayana Hrudayalaya share price rise so much?

Ans. The rally came from a strong post-Covid earnings recovery, with net profit rising from about Rs 342 crore in FY22 to Rs 810 crore in FY26. A high-margin Cayman Islands business and the 2025 UK acquisition added further growth.

What were Narayana Hrudayalaya Q1 FY27 results?

Ans. Operating revenue rose about 78% year on year to approximately Rs 2,684 crore, helped by the newly acquired UK hospitals. Net profit rose about 5% to Rs 207 crore, as EBITDA margin fell to 18.8% from 23.9%.

What is Practice Plus Group?

Ans. Practice Plus Group Hospitals is the fifth-largest private hospital chain in the UK, with 12 hospitals and surgical centres. Narayana Health bought it for approximately Rs 2,200 crore, completing the deal on 6 November 2025.

What is the 52-week high and low of Narayana Hrudayalaya?

Ans. The Narayana Hrudayalaya share price has a 52-week high of Rs 2,093.30 and a 52-week low of Rs 1,589 on NSE. It closed at approximately Rs 1,909.70 on 10 September 2026.

How has this hospital stock performed in the last year?

Ans. The one-year return is about 10.39%, ranking 71st out of 101 stocks screened. Gains slowed as the UK acquisition diluted margins and raised debt, even though revenue grew sharply.

What is the Narayana Hrudayalaya share price target?

Ans. The highest recent target from a domestic brokerage is Rs 2,310, set in June 2026, while the analyst consensus was around Rs 2,152 in July 2026. Targets are estimates and not guaranteed.

Is this hospital stock a good long-term investment?

Ans. The company has a strong track record, rising profits and a PE of about 47, below the industry PE of about 68. However, higher debt and UK integration are real risks, so staggered investing and advice from a SEBI-registered advisor are sensible.